Christine Feig
Impact in
- Oncology top 0.5%
- Pancreatic and Hepatic Oncology Research
- Cancer Cells and Metastasis
- Cancer Immunotherapy and Biomarkers
- Cancer Research top 0.5%
- MicroRNA in disease regulation
Papers in
-
- Phagocytosis and Immune Regulation 6
-
- MicroRNA in disease regulation 3
- Cancer-related molecular mechanisms research 3
- Co-authors
- David A. TuvesonDerek ChanAlbrecht NeeßeNatalie CookMarcus E. PeterAarthi GopinathanDuncan I. JodrellDouglas T. Fearon
- Journals
- Gut (2 papers)Nature (2 papers)The EMBO Journal (2 papers)Genome biology (2 papers)Proceedings of the National Academy of Sciences (2 papers)
- Partner nations
- United KingdomUnited StatesGermany
In The Last Decade
Christine Feig
25 papers receiving 6.5k citations
Hit Papers
Peers
Comparison fields: 5 of 128
- Oncology 3.9k
- Cancer Research 1.7k
- Immunology 1.9k
- Molecular Biology 3.0k
- Biotechnology 272
Countries citing papers authored by Christine Feig
This map shows the geographic impact of Christine Feig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christine Feig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christine Feig more than expected).
Fields of papers citing papers by Christine Feig
This network shows the impact of papers produced by Christine Feig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christine Feig. The network helps show where Christine Feig may publish in the future.
Co-authors
The 25 scholars most cited alongside Christine Feig, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2020 | 73 | |
| 2 | 2018 | 31 | |
| 3 | 2018 | 98 | |
| 4 | 2017 | 48 | |
| 5 | 2016 | 108 | |
| 6 | 2014 | 3 | |
| 7 | 2013 | 5 | |
| 8 | 2013 | 300 | |
| 9 | Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer Hit paper breakdown → | 2013 | 1490 |
| 10 | Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer Hit paper breakdown → | 2012 | 837 |
| 11 | 2011 | 340 | |
| 12 | 2010 | 300 | |
| 13 | Stromal biology and therapy in pancreatic cancer Hit paper breakdown → | 2010 | 604 |
| 14 | 2008 | 188 | |
| 15 | 2008 | 1 | |
| 16 | 2007 | 67 | |
| 17 | 2007 | 193 | |
| 18 | 2006 | 121 | |
| 19 | 2006 | 192 | |
| 20 | 2005 | 123 |
About Christine Feig
Christine Feig is a scholar working on Immunology, Cancer Research, Oncology, Molecular Biology and Physiology, having authored 25 papers that have together received 6.6k indexed citations. Recurring topics across this work include Phagocytosis and Immune Regulation (6 papers), Cell death mechanisms and regulation (5 papers), Pancreatic and Hepatic Oncology Research (4 papers), MicroRNA in disease regulation (3 papers), Cancer Cells and Metastasis (3 papers), Cancer-related molecular mechanisms research (3 papers), RNA Research and Splicing (3 papers) and Genomics and Chromatin Dynamics (3 papers). The work is most often cited by research in Oncology (3.9k citations), Cancer Research (1.7k citations), Immunology (1.9k citations), Molecular Biology (3.0k citations) and Biotechnology (272 citations). Christine Feig has collaborated with scholars based in United Kingdom, United States and Germany. Frequent co-authors include David A. Tuveson, Derek Chan, Albrecht Neeße, Natalie Cook, Marcus E. Peter, Aarthi Gopinathan, Duncan I. Jodrell, Douglas T. Fearon, Matthew Kraman and R. J. Wells. Their work appears in journals such as Gut, Nature, The EMBO Journal, Genome biology and Proceedings of the National Academy of Sciences.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.